Introduction: In the last decade, multiparametric magnetic resonance imaging (MRI) has
achieved tremendous advances in applications to amyotrophic lateral sclerosis (ALS) to …

In patients with ALS, conventional MR imaging is frequently noninformative, and its use has
been restricted to excluding other conditions that can mimic ALS. Conversely, the extensive …

Objective Reliable biomarkers for amyotrophic lateral sclerosis (ALS) are needed, given the
clinical heterogeneity of the disease. Here, we provide proof‐of‐concept for using …

Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative, clinically
heterogeneous syndrome pathologically overlapping with frontotemporal dementia. To date …

Introduction: Several neuroimaging techniques have been used to define in vivo markers of
pathological alterations underlying amyotrophic lateral sclerosis (ALS). Growing evidence …

Background Despite significant advances in quantitative neuroimaging, the diagnosis of
ALS remains clinical and MRI-based biomarkers are not currently used to aid the diagnosis …

Recently proposed biomarkers in ALS have huge practical potential to ascertain phenotype-
associated molecular or imaging profiles early in the course of the disease, track disease …

Importance of the field: With the emergence of therapeutic candidates for the incurable and
rapidly progressive neurodegenerative condition of amyotrophic lateral sclerosis (ALS), it …

Neuroimaging in Amyotrophic Lateral Sclerosis (ALS) has steadily evolved from an
academic exercise to a powerful clinical tool for detecting and following pathological …

Amyotrophic lateral sclerosis (ALS) is now recognised to be a heterogeneous
neurodegenerative syndrome of the motor system and its frontotemporal cortical …